BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$2.34
-0.09 (-3.51%)
Open$2.43
Previous Close$2.43
Day High$2.45
Day Low$2.29
52W High$80.70
52W Low$2.54
Volume—
Avg Volume113.4K
Market Cap3.48M
P/E Ratio—
EPS$-6.89
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,113.2% upside
Current
$2.34
$2.34
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.59M | 608.9K | 644.1K |
| Net Income | -11,116,099 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -7,506,030 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |